goetzpartners advised Evotec SE

Fortlane Partners advised Evotec SE (“Evotec”), the publicly listed life science company headquartered in Hamburg, on its acquisition of Central Glass Germany GmbH (“Central Glass Germany”), a fully operational EU GMP certified facility in Halle/Westphalia, from the Japanese chemical manufacturing company Central Glass Co. Ltd. for a purchase price of € 1 to expand its clinical and commercial drug substance manufacturing platform.

Going forward, Central Glass Germany will operate as Evotec Drug Substance (Germany) GmbH (“Evotec DS”). The Company is located on a pharmaceutical manufacturing campus in Halle/Westphalia, Germany and is operating with a team of ~60 chemical manufacturing experts. The facility is EU cGMP certified and provides highly flexible drug substance manufacturing space with over 5,000 square meters of floor space.

The acquisition of the Central Glass site in Germany enhances and accelerates Evotec’s strategy of pursuing integrated discovery and development of new medicines that matter. The significant reactor capacity and long-standing chemical expertise brought in by Evotec DS provide a high quality, European-based solution to Evotec’s partners for the development and commercialization of drug substance. Once integrated into Evotec’s existing drug substance development and manufacturing platform, the new site will offer the Company’s partners highly flexible product lifecycle management strategies, particularly in the field of precision medicines and in rare diseases.

Dr. Werner Lanthaler, Chief Executive Officer of Evotec, commented: “Our understanding of diseases continuously grows in depth – and with it the number of rare diseases that we can meaningfully distinguish and target with precision medicine. Evotec DS reinforces our commitment to rare diseases by integrating the manufacturing of such drugs into the drug discovery and development continuum. We very warmly welcome the team into the Evotec family and are excited to leverage their skills and expertise for our partners.”

The transaction is subject to customary closing conditions and is anticipated to close on 1 November 2022. After the successful acquisition of Evotec (Modena) Srl, formerly Rigenerand Srl, this is the second transaction in which Fortlane Partners acted as sole M&A financial advisor to Evotec. This transaction further demonstrates Fortlane Partners' ability to achieve outperforming results and underlines our competence as advisor of choice in the Healthcare & Life Sciences space.

About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company’s 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

Transaction team:

Ulrich Kinzel
Managing Director
 

Youchen Xin
Associate Director

Richard Arand
Associate

Charlotte Prautzsch
Associate

Robert Lenigas
Analyst